# Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

> **NCT06107205** · PHASE1 · COMPLETED · sponsor: **Shanghai Auzone Biological Technology Co., Ltd.** · enrollment: 29 (actual)

## Conditions studied

- Healthy Adult Subjects

## Interventions

- **DRUG:** TTYP01
- **DRUG:** Radicava
- **DRUG:** Radicava ORS

## Key facts

- **NCT ID:** NCT06107205
- **Lead sponsor:** Shanghai Auzone Biological Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-07
- **Primary completion:** 2023-12-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06107205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06107205, "Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06107205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*